듀켐바이오

176750KOSDAQSector: Pharma & Biotech

₩5,740▲ 2.14%Market cap ₩163.5BAs of Jul 21, 2026 close · updated once daily

Grade B61.7 ptsTop 30% of 2,523 stocks

Financial strength

68.1

Growth momentum

67.6

Price attractiveness

50.2

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Financial strength

68.1

How much debt does it carry relative to equity?

Debt-to-equity ratio

57.8%

✗ Below median · Top 55.1% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

157.5%

✗ Below median · Top 56.7% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

19.3%

✓ Above median · Top 8% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

13.2%

✓ Above median · Top 7.9% in sector

Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

Growth momentum

67.6

How much did revenue grow in a year?

Revenue growth (YoY)

8.3%

✓ Above median · Top 43.2% in sector

Sector median 6.4%

Did core profits grow in a year?

Operating income change (YoY)

46.6%

✓ Above median · Top 21.7% in sector

Sector median 3.6%

Source filing: annual report (consolidated) — view original ↗

Price attractiveness

50.2

Is the price expensive relative to earnings?

P/E (price-to-earnings)

25.2x

✓ Above median · Top 28.7% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

3.32x

✗ Below median · Top 70.9% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15